Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency
{{output}}
Non-industry organizations, including academia, charities, and public institutes, increasingly contribute to rare disease medicine development. In this study, we reviewed orphan designations (ODs) granted between 2000 and 2022, comparing non-industry and indus... ...
